Yixintang Pharmaceutical Group Co., Ltd. (SHE:002727)
China · Delayed Price · Currency is CNY 12.78
+0.05 (0.39%)
May 8, 2026, 3:04 PM CST
SHE:002727 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 17,003 | 17,336 | 17,462 | 16,877 | 17,124 | 14,275 |
Other Revenue | - | - | 538.72 | 503.73 | 307.42 | 312.21 |
| 17,003 | 17,336 | 18,000 | 17,380 | 17,432 | 14,587 | |
Revenue Growth (YoY) | -3.76% | -3.69% | 3.57% | -0.29% | 19.50% | 15.26% |
Cost of Revenue | 11,398 | 11,680 | 12,428 | 11,798 | 11,486 | 9,320 |
Gross Profit | 5,605 | 5,656 | 5,573 | 5,582 | 5,946 | 5,267 |
Selling, General & Admin | 4,888 | 4,941 | 5,166 | 4,663 | 4,512 | 4,087 |
Research & Development | 8.88 | 10.59 | 9.71 | 10.2 | 8.74 | 5.39 |
Other Operating Expenses | -43.8 | -41.48 | 7.67 | 32.62 | 17.17 | -13.93 |
Operating Expenses | 4,853 | 4,911 | 5,190 | 4,739 | 4,628 | 4,082 |
Operating Income | 752.2 | 745.35 | 383.26 | 843.93 | 1,318 | 1,185 |
Interest Expense | -0.83 | - | -146.04 | -135.34 | -93.72 | -136.22 |
Interest & Investment Income | - | - | 47.04 | 86.48 | 7.49 | 53.52 |
Currency Exchange Gain (Loss) | - | - | - | - | 0.23 | -0.09 |
Other Non Operating Income (Expenses) | -156.32 | -170.05 | -7.75 | -93.76 | 1.48 | -4.53 |
EBT Excluding Unusual Items | 595.05 | 575.3 | 276.51 | 701.32 | 1,233 | 1,098 |
Impairment of Goodwill | - | - | -26.77 | -11.65 | -12.29 | -10.97 |
Gain (Loss) on Sale of Investments | -6.15 | -7.1 | -3.43 | -8.36 | -5.72 | -5.77 |
Gain (Loss) on Sale of Assets | 9.65 | 8.79 | 3.18 | 1.12 | -13.83 | -13.41 |
Asset Writedown | -170.19 | -170.4 | -2.17 | -2.93 | -13.85 | -2.71 |
Other Unusual Items | - | - | -40 | 23.07 | 47.48 | 31.29 |
Pretax Income | 428.36 | 406.59 | 207.31 | 702.56 | 1,235 | 1,097 |
Income Tax Expense | 143.09 | 134.89 | 97.02 | 142.15 | 222 | 179.32 |
Earnings From Continuing Operations | 285.27 | 271.71 | 110.29 | 560.41 | 1,013 | 917.21 |
Minority Interest in Earnings | -6.1 | -8.27 | 3.85 | -10.97 | -2.98 | 4.38 |
Net Income | 279.17 | 263.43 | 114.14 | 549.44 | 1,010 | 921.58 |
Net Income to Common | 279.17 | 263.43 | 114.14 | 549.44 | 1,010 | 921.58 |
Net Income Growth | 764.59% | 130.80% | -79.23% | -45.60% | 9.59% | 16.66% |
Shares Outstanding (Basic) | 576 | 576 | 592 | 597 | 593 | 590 |
Shares Outstanding (Diluted) | 576 | 576 | 592 | 597 | 595 | 592 |
Shares Change (YoY) | -2.28% | -2.70% | -0.76% | 0.27% | 0.50% | 3.32% |
EPS (Basic) | 0.48 | 0.46 | 0.19 | 0.92 | 1.70 | 1.56 |
EPS (Diluted) | 0.48 | 0.46 | 0.19 | 0.92 | 1.70 | 1.56 |
EPS Growth | 784.75% | 137.21% | -79.07% | -45.75% | 9.05% | 12.91% |
Free Cash Flow | 1,584 | 1,355 | 1,466 | 1,862 | 2,148 | 1,400 |
Free Cash Flow Per Share | 2.75 | 2.35 | 2.48 | 3.12 | 3.61 | 2.36 |
Dividend Per Share | - | - | 0.300 | 0.400 | 0.400 | 0.300 |
Dividend Growth | - | - | -25.00% | - | 33.33% | - |
Gross Margin | 32.97% | 32.62% | 30.96% | 32.12% | 34.11% | 36.11% |
Operating Margin | 4.42% | 4.30% | 2.13% | 4.86% | 7.56% | 8.13% |
Profit Margin | 1.64% | 1.52% | 0.63% | 3.16% | 5.79% | 6.32% |
Free Cash Flow Margin | 9.32% | 7.82% | 8.14% | 10.71% | 12.32% | 9.60% |
EBITDA | 876.47 | 866.67 | 492.77 | 968.59 | 1,432 | 1,283 |
EBITDA Margin | 5.16% | 5.00% | 2.74% | 5.57% | 8.22% | 8.80% |
D&A For EBITDA | 124.27 | 121.32 | 109.51 | 124.66 | 114.46 | 98.08 |
EBIT | 752.2 | 745.35 | 383.26 | 843.93 | 1,318 | 1,185 |
EBIT Margin | 4.42% | 4.30% | 2.13% | 4.86% | 7.56% | 8.13% |
Effective Tax Rate | 33.40% | 33.17% | 46.80% | 20.23% | 17.98% | 16.35% |
Revenue as Reported | - | - | 18,000 | 17,380 | 17,432 | 14,587 |
Advertising Expenses | - | - | 62.9 | 49.55 | 49.28 | 42.16 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.